The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
Official Title: An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
Study ID: NCT04410367
Brief Summary: An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States
Yale School of Medicine, New Haven, Connecticut, United States
Miami Cancer Institute, Miami, Florida, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Washington University School of Medicine Center for Clinical Imaging Research, Saint Louis, Missouri, United States
NYU Langone Health, New York, New York, United States
University Hospital Cleveland, Cleveland, Ohio, United States
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, Salt Lake City, Utah, United States
Name: Eugene Teoh, MD
Affiliation: Blue Earth Diagnostics
Role: STUDY_DIRECTOR
Name: Rupesh Kotecha, MD
Affiliation: Miami Cancer Institute
Role: PRINCIPAL_INVESTIGATOR